title: 99mTc-EDDA/HYNIC-TOC somatostatin receptor scintigraphy in daily clinical practice.
abstract: BACKGROUND
  This study aimed to assess the impact of 99mTc-EDDA/HYNIC-TOC (99mTc-TOC) somatostatin receptor scintigraphy (SRS) in clinical practice.
  
  
  METHODS
  One hundred seventeen patients were divided into 6 groups: 1, initial detection and localization of suspected neuroendocrine tumor (NET); 2, tumor staging before therapy; 3, staging of NET of unknown origin, 4, restaging after surgery of primary tumor; 5, diagnosis of solitary pulmonary nodules (SPNs), and 6, follow-up after "cold" somatostatin analogues treatment.
  
  
  RESULTS
  In group 1, clinical suspicions were not confirmed in any of the patients; in group 2, most of the primary lesions showed overexpression of somatostatin receptors (SSRT); in group 3, the primary tumor was not identified in any of the patients; in group 4, recurrences were depicted in 7 out of 47 patients; in group 5, only 1 malignant SPN was detected, and in group 6, regression of primary mass and metastases were seen on follow-up SRS in 1 patient.
  
  
  CONCLUSIONS
  99mTc-TOC SRS is useful in staging of SSRT-overexpressing tumors of known and unknown primary origin, as well as in restaging after primary tumor surgery. This method is less effective in detecting suspected NET and assessing SPNs. Further investigation is necessary to evaluate the usefulness of SRS in monitoring patients after biological treatment.
authors.affiliation: Chair and Department of Nuclear Medicine, Medical University of Lublin, 20-954 Lublin, Poland. beata.chrapko@wp.pl
authors.forename: Beata Ewa
authors.initials: BE
authors.lastname: Chrapko
authors.forename: Anna
authors.initials: A
authors.lastname: Nocuń
authors.forename: Renata
authors.initials: R
authors.lastname: Gołebiewska
authors.forename: Bogusław
authors.initials: B
authors.lastname: Stefaniak
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Korobowicz
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Czekajska-Chehab
authors.forename: Marek
authors.initials: M
authors.lastname: Sawicki
authors.forename: Wojciech Piotr
authors.initials: WP
authors.lastname: Polkowski
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000379:methods; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging / Q000379:methods; D009369:Neoplasms / Q000175:diagnosis / Q000473:pathology*; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000473:pathology; D015282:Octreotide / Q000031:analogs & derivatives* / Q000494:pharmacology; D015609:Organotechnetium Compounds / Q000494:pharmacology*; D011877:Radionuclide Imaging / Q000379:methods*; D017481:Receptors, Somatostatin / Q000378:metabolism*
chemical_list: D015609:Organotechnetium Compounds; D017481:Receptors, Somatostatin; C410263:technetium Tc 99m hydrazinonicotinyl-Tyr(3)-octreotide; D015282:Octreotide